Interspecies Scaling of Biliary Excreted Drugs: A Comparison of Several Methods**The views expressed in this article are those of the author and do not reflect the official policy of the FDA. No official support or endorsement by the FDA is intended or should be inferred.-Reference-Cited by-同舟云学术

Interspecies Scaling of Biliary Excreted Drugs: A Comparison of Several Methods**The views expressed in this article are those of the author and do not reflect the official policy of the FDA. No official support or endorsement by the FDA is intended or should be inferred.

Published:2005-04 Issue:4 Volume:94 Page:883-892
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Mahmood Iftekhar

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference19 articles.

1. Tissue distribution: Interspecies differences: Principles of animal extrapolation;Calabrese,1991

2. Interspecies scaling of biliary excreted drugs;Mahmood;J Pharm Sci,2002

3. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist;Ward;Drug Metab Disp,1999

4. Physiological parameters in laboratory animals and humans;Davies;Pharm Res,1993

5. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance;Ward;Drug Metab Dispos,2004

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist;European Journal of Clinical Pharmacology;2023-04-15

2. ADME Optimization in Drug Discovery;The Handbook of Medicinal Chemistry;2023-02-03

3. Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs;Journal of Medicinal Chemistry;2021-05-19

4. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery;Expert Opinion on Drug Discovery;2019-09-20

5. Misconceptions and issues regarding allometric scaling during the drug development process;Expert Opinion on Drug Metabolism & Toxicology;2018-07-19